


EXPrESSIVE Phase 3 Trial Countries of MK-8527

Seventeen countries in total are hosting sites for Merck's Phase 3 trials of the monthly PrEP pill, MK-8527.
EXPrESSIVE-11 launched in August 2025; EXPrESSIVE-10 launched in November 2025.



EXPrESSIVE-11

- Approximately 4,390 participants
- Sexually active cisgender men, MSM, transgender men and women, gender non-binary persons who could benefit from PrEP

▪ [ClinicalTrials.gov Study Record](#)

EXPrESSIVE-10

- Approximately 4,580 participants
- Sexually active cisgender adolescent girls, young women, and women who could benefit from PrEP

▪ [ClinicalTrials.gov Study Record](#)